General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Excreted Unchanged %
30-60
Half-Life (Normalesrd) Hours
4-6/10
Plasma Protein Binding %
>99
Volume Of Distribution L/Kg
0.13-0.25
Dose For Normal Renal Function
30-60 mg load,then 15-30 mg q6h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25-50% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990; 39: 86-109. [PMID: 2178916] / Otti T, Weindel M, Bastani B. Ketorolac induced acute reversible hearing loss in a patient maintained on CAPD [Letter]. Clin Nephrol. 1997; 47: 208-9. [PMID: 9105776]
Toxicity Notes
Acute hearing loss in ESRD.